Amsacrine (Synonyms: 安吖啶; m-AMSA; acridinyl anisidide)

目录号: HY-13551 纯度: 99.91%: FAQs
Data Sheet SDS COA 产品使用指南技术支持

Amsacrine (m-AMSA; acridinyl anisidide) 是肿瘤细胞 DNA 嵌入剂，还能抑制拓扑异构酶 II。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Amsacrine Chemical Structure

CAS No. : 51264-14-3

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥792	In-stock
5 mg	￥720	In-stock
10 mg	￥1125	In-stock
25 mg	￥2250	In-stock
50 mg	￥3600	In-stock
100 mg	￥5760	In-stock
200 mg		询价
500 mg		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Amsacrine:

MCE 顾客使用本产品发表的 5 篇科研文献

Amsacrine 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Topoisomerase 亚型特异性产品:

查看所有亚型

Topoisomerase Topo I Topo II

生物活性
实验参考方法
纯度 & 产品资料
参考文献

生物活性

Amsacrine (m-AMSA; acridinyl anisidide) is an inhibitor of topoisomerase II, and acts as an antineoplastic agent which can intercalates into the DNA of tumor cells.

IC₅₀ & Target^[1]

Topoisomerase II

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
2008	IC₅₀	4.31 μM Compound: m-AMSA	Cytotoxicity against human 2008 cells after 72 hrs by MTT assay Cytotoxicity against human 2008 cells after 72 hrs by MTT assay	[PMID: 19101158]
A2780	GI₅₀	0.027 μM Compound: m-AMSA	Growth inhibition of human A2780 cells incubated for 72 hrs by trypan blue assay Growth inhibition of human A2780 cells incubated for 72 hrs by trypan blue assay	[PMID: 32435372]
A2780	IC₅₀	0.1 μM Compound: m-AMSA	Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells. Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.	[PMID: 7658436]
A-431	IC₅₀	0.17 μM Compound: 1, m-AMSA	Growth inhibition in human A431 cells after 72 hrs by trypan blue assay Growth inhibition in human A431 cells after 72 hrs by trypan blue assay	[PMID: 21216603]
A-431	IC₅₀	5.89 μM Compound: m-AMSA	Cytotoxicity against human A431 cells after 72 hrs by MTT assay Cytotoxicity against human A431 cells after 72 hrs by MTT assay	[PMID: 19101158]
A549	IC₅₀	0.03 μM Compound: 1	Inhibitory activity against A549 cell line using MTT assay(Wild type p53) Inhibitory activity against A549 cell line using MTT assay(Wild type p53)	[PMID: 10780913]
A549	IC₅₀	22.2 μM Compound: m-Amsa	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33479643]
A549	IC₅₀	3.52 μM Compound: m-AMSA	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 19101158]
A549	IC₅₀	5.96 μM Compound: 2; m-AMSA	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 27060757]
CCRF-CEM	IC₅₀	0.03 μM Compound: m-AMSA	Antiproliferative against human CCRF-CEM cells incubated for 72 hrs by MTT assay Antiproliferative against human CCRF-CEM cells incubated for 72 hrs by MTT assay	[PMID: 31635931]
CCRF-CEM	IC₅₀	0.18 μM Compound: 2; m-AMSA	Antiproliferative activity against human CCRF-CEM cells after 48 hrs by MTT assay Antiproliferative activity against human CCRF-CEM cells after 48 hrs by MTT assay	[PMID: 27060757]
CCRF-CEM	IC₅₀	130 nM Compound: amsacrine	Cytotoxicity against human CCRF-CEM cells after 72 hrs Cytotoxicity against human CCRF-CEM cells after 72 hrs	[PMID: 18329887]
CHO-AA8	IC₅₀	0.6 nM Compound: Amsacrine	Inhibitory activity of compound for AA8 cells to reduce cell density by 50% (exposed to compound for 4 hours) Inhibitory activity of compound for AA8 cells to reduce cell density by 50% (exposed to compound for 4 hours)	[PMID: 2909741]
COLO 205	IC₅₀	1.1 μM Compound: Amsacrine	Antiproliferative activity against human COLO205 cells after 72 hrs by MTT assay Antiproliferative activity against human COLO205 cells after 72 hrs by MTT assay	[PMID: 22546208]
DLD-1	IC₅₀	0.08 μM Compound: amsacrine	Cytotoxicity against human DLD1 cells by Hoechst test Cytotoxicity against human DLD1 cells by Hoechst test	[PMID: 18656367]
DLD-1	IC₅₀	0.57 μM Compound: amsacrine	Cytotoxicity against human DLD1 cells by resazurin reduction test Cytotoxicity against human DLD1 cells by resazurin reduction test	[PMID: 18656367]
DU-145	IC₅₀	0.3 μM Compound: Amsacrine	Antiproliferative activity against human DU145 cells after 72 hrs by MTT assay Antiproliferative activity against human DU145 cells after 72 hrs by MTT assay	[PMID: 22546208]
F460pv8/eto	IC₅₀	0.04 μM Compound: 1	Inhibitory activity against F460pv8/eto cell line using MTT assay Inhibitory activity against F460pv8/eto cell line using MTT assay	[PMID: 10780913]
Fibroblast	IC₅₀	2 μM Compound: amsacrine	Cytotoxicity against human fibroblast cells by Hoechst test Cytotoxicity against human fibroblast cells by Hoechst test	[PMID: 18656367]
Fibroblast	IC₅₀	4.2 μM Compound: amsacrine	Cytotoxicity against human fibroblast cells by resazurin reduction test Cytotoxicity against human fibroblast cells by resazurin reduction test	[PMID: 18656367]
HCC1937	IC₅₀	7.85 μM Compound: m-AMSA	Antiproliferative activity against human HCC1937 cells harboring BRCA1 mutant after 72 hrs by MTT assay Antiproliferative activity against human HCC1937 cells harboring BRCA1 mutant after 72 hrs by MTT assay	[PMID: 28763648]
HCT-116	IC₅₀	< 1 μM Compound: m-AMSA	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 29954683]
HCT-116	IC₅₀	0.7 μM Compound: m-AMSA	Cytotoxicity against human HCT116 cells by XTT assay Cytotoxicity against human HCT116 cells by XTT assay	[PMID: 17368022]
HCT-116	IC₅₀	0.93 μM Compound: 2; m-AMSA	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 27060757]
HCT-116	IC₅₀	3.89 μM Compound: m-AMSA	Antiproliferative activity against human HCT116 cells expressing topoisomerase-1 after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells expressing topoisomerase-1 after 72 hrs by MTT assay	[PMID: 28763648]
HCT-15	IC₅₀	0.3 μM Compound: Amsacrine	Antiproliferative activity against human HCT15 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT15 cells after 72 hrs by MTT assay	[PMID: 22546208]
HCT-8	IC₅₀	0.3 μM Compound: Amsacrine	Antiproliferative activity against human HCT8 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 22546208]
HEK293	IC₅₀	5 μM Compound: amsacrine	Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy	[PMID: 18788725]
HeLa	IC₅₀	0.012 μM Compound: 1, m-AMSA	Growth inhibition in human HeLa cells after 72 hrs by trypan blue assay Growth inhibition in human HeLa cells after 72 hrs by trypan blue assay	[PMID: 21216603]
HeLa	IC₅₀	0.012 μM Compound: m-amsacrine	Antiproliferative activity against human HeLa cells after 72 hrs by trypan blue test Antiproliferative activity against human HeLa cells after 72 hrs by trypan blue test	[PMID: 18077173]
HeLa	GI₅₀	0.031 μM Compound: m-AMSA	Growth inhibition of human HeLa cells incubated for 72 hrs by trypan blue assay Growth inhibition of human HeLa cells incubated for 72 hrs by trypan blue assay	[PMID: 32435372]
HeLa	IC₅₀	0.34 μM Compound: 2; m-AMSA	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 27060757]
HeLa	EC₅₀	0.72 μM Compound: m-AMSA	Tested for inhibitory activity against Topoisomerase II isolated from HeLa cells by using SDS-K+ precipitation method Tested for inhibitory activity against Topoisomerase II isolated from HeLa cells by using SDS-K+ precipitation method	10.1016/S0960-894X(00)80048-7
HeLa	EC₅₀	0.72 μM Compound: mAMSA	Compound was tested for topoisomerase II inhibition in purified HeLa cells by SDS/K+ precipitation method Compound was tested for topoisomerase II inhibition in purified HeLa cells by SDS/K+ precipitation method	10.1016/0960-894X(95)00044-T
HeLa	EC₅₀	0.72 μM Compound: m-AMSA	Inhibitory activity in a cell-free assay of DNA cleavage mediated by purified HeLa cell topoisomerase II. Inhibitory activity in a cell-free assay of DNA cleavage mediated by purified HeLa cell topoisomerase II.	10.1016/0960-894X(95)00043-S
HeLa	EC₅₀	0.72 μM Compound: 5 (m-AMSA)	Tested for inhibition of topoisomerase II isolated from HeLa cells by DNA-cleavage assay Tested for inhibition of topoisomerase II isolated from HeLa cells by DNA-cleavage assay	[PMID: 8410993]
HeLa	IC₅₀	19.19 μM Compound: m-AMSA	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 28511910]
HeLa	IC₅₀	9.5 μM Compound: m-AMSA	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 19364657]
HeLa	IC₅₀	9.5 μM Compound: Amsacrine	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 18035542]
HepG2	IC₅₀	5.21 μM Compound: m-AMSA	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 28511910]
HL-60	IC₅₀	0.0051 μM Compound: m-amsacrine	Antiproliferative activity against human HL60 cells after 72 hrs by trypan blue test Antiproliferative activity against human HL60 cells after 72 hrs by trypan blue test	[PMID: 18077173]
HL-60	IC₅₀	0.006 μM Compound: 1, m-AMSA	Growth inhibition in human HL60 cells after 72 hrs by trypan blue assay Growth inhibition in human HL60 cells after 72 hrs by trypan blue assay	[PMID: 21216603]
HL-60	IC₅₀	0.08 μM Compound: Amsacrine	Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay	[PMID: 22546208]
HL-60	IC₅₀	1.15 μM Compound: m-AMSA	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 19101158]
HT-1080	GI₅₀	1.6 μM Compound: m-Amsa	Cytocidal activity against human HT1080 cells assessed as growth inhibition after 48 hrs by SRB assay Cytocidal activity against human HT1080 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 22503207]
HT-1080	GI₅₀	1.6 μM Compound: m-Amsa	Antiproliferative activity against human HT1080 cells after 48 hrs by SRB assay Antiproliferative activity against human HT1080 cells after 48 hrs by SRB assay	[PMID: 18403058]
HT-29	GI₅₀	16.8 μM Compound: m-Amsa	Cytocidal activity against human HT-29 cells assessed as growth inhibition after 48 hrs by SRB assay Cytocidal activity against human HT-29 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 22503207]
HT-29	GI₅₀	16.8 μM Compound: m-Amsa	Antiproliferative activity against human HT-29 cells after 48 hrs by SRB assay Antiproliferative activity against human HT-29 cells after 48 hrs by SRB assay	[PMID: 18403058]
HT-29	IC₅₀	559 nM Compound: m-AMSA	Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay	[PMID: 2778449]
Jurkat	IC₅₀	< 1 μM Compound: 3	Concentration required to reduce growth of human jurkat leukemia cells to 50% of control cultures, determined using a 72 hr continuous exposure Concentration required to reduce growth of human jurkat leukemia cells to 50% of control cultures, determined using a 72 hr continuous exposure	[PMID: 8182707]
Jurkat	IC₅₀	0.02 μM Compound: amsacrine	Cytotoxicity against human Jurkat cells by Hoechst test Cytotoxicity against human Jurkat cells by Hoechst test	[PMID: 18656367]
Jurkat	IC₅₀	0.08 μM Compound: amsacrine	Cytotoxicity against human Jurkat cells by resazurin reduction test Cytotoxicity against human Jurkat cells by resazurin reduction test	[PMID: 18656367]
K562	IC₅₀	0.023 μM Compound: amsacrine (m-AMSA)	Cytotoxicity against human K562 cells after 5 days by XTT assay Cytotoxicity against human K562 cells after 5 days by XTT assay	[PMID: 18076140]
K562	IC₅₀	0.71 μM Compound: m-AMSA	Antiproliferative against human K562 cells incubated for 72 hrs by MTT assay Antiproliferative against human K562 cells incubated for 72 hrs by MTT assay	[PMID: 31635931]
K562	IC₅₀	0.88 μM Compound: m-AMSA	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 28511910]
K562	IC₅₀	13.8 μM Compound: m-Amsa	Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33479643]
K562	IC₅₀	19.9 μM Compound: m-AMSA	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 19364657]
K562	IC₅₀	19.9 μM Compound: Amsacrine	Antiproliferative activity against human K562 cells after 72 hrs by MTT assay Antiproliferative activity against human K562 cells after 72 hrs by MTT assay	[PMID: 18035542]
M21	GI₅₀	49.6 μM Compound: m-Amsa	Cytocidal activity against human M21 cells assessed as growth inhibition after 48 hrs by SRB assay Cytocidal activity against human M21 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 22503207]
M21	GI₅₀	49.6 μM Compound: m-Amsa	Antiproliferative activity against human M21 cells after 48 hrs by SRB assay Antiproliferative activity against human M21 cells after 48 hrs by SRB assay	[PMID: 18403058]
M4Beu cell line	IC₅₀	0.4 μM Compound: amsacrine	Cytotoxicity against human M4Beu cells by Hoechst test Cytotoxicity against human M4Beu cells by Hoechst test	[PMID: 18656367]
M4Beu cell line	IC₅₀	0.74 μM Compound: amsacrine	Cytotoxicity against human M4Beu cells by resazurin reduction test Cytotoxicity against human M4Beu cells by resazurin reduction test	[PMID: 18656367]
MCF7	IC₅₀	0.075 μM Compound: 1	Inhibitory activity against MCF-7 wt cell line using MTT assay (ER+,pgR+,wildtype p53) Inhibitory activity against MCF-7 wt cell line using MTT assay (ER+,pgR+,wildtype p53)	[PMID: 10780913]
MCF7	IC₅₀	0.075 μM Compound: 1	Inhibitory activity against MCF7wt cell line using MTT assay Inhibitory activity against MCF7wt cell line using MTT assay	[PMID: 10780913]
MCF7	IC₅₀	0.91 μM Compound: m-Amsa	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31421632]
MCF7	IC₅₀	21.7 μM Compound: m-AMSA	Cytotoxicity against human MCF7 cells by XTT assay Cytotoxicity against human MCF7 cells by XTT assay	[PMID: 18093835]
MCF7	IC₅₀	21.7 μM Compound: m-AMSA	Cytotoxicity against human MCF7 cells by XTT assay Cytotoxicity against human MCF7 cells by XTT assay	[PMID: 17368022]
MCF7	IC₅₀	26.76 μM Compound: 2; m-AMSA	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 27060757]
MCF7	IC₅₀	5.13 μM Compound: m-AMSA	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 19101158]
MCF7	GI₅₀	5.6 μM Compound: m-Amsa	Cytocidal activity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay Cytocidal activity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 22503207]
MCF7	GI₅₀	5.6 μM Compound: m-Amsa	Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 18403058]
MCF7	IC₅₀	8.7 μM Compound: m-AMSA	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 28763648]
MDA-MB-231	IC₅₀	0.14 μM Compound: 1	Inhibitory activity against MDA-231 cell line using MTT assay (ER-,EGFR+,mutant p53) Inhibitory activity against MDA-231 cell line using MTT assay (ER-,EGFR+,mutant p53)	[PMID: 10780913]
MDA-MB-231	IC₅₀	10.05 μM Compound: m-AMSA	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 29954683]
MDA-MB-468	IC₅₀	0.49 μM Compound: 1	Inhibitory activity against MDA-468 cell line using MTT assay (ER-, amplified EGFR, mutant p53) Inhibitory activity against MDA-468 cell line using MTT assay (ER-, amplified EGFR, mutant p53)	[PMID: 10780913]
MDA-MB-468	IC₅₀	8.5 μM Compound: m-AMSA	Cytotoxicity against human MDA-MB468 cells by XTT assay Cytotoxicity against human MDA-MB468 cells by XTT assay	[PMID: 17368022]
MRC5	IC₅₀	15.4 μM Compound: m-Amsa	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33479643]
MSTO-211H	GI₅₀	0.019 μM Compound: m-AMSA	Growth inhibition of human MSTO-211H cells incubated for 72 hrs by trypan blue assay Growth inhibition of human MSTO-211H cells incubated for 72 hrs by trypan blue assay	[PMID: 32435372]
NCI/ADR-RES	IC₅₀	1.165 μM Compound: 1	Inhibitory activity against MCF-7/adr cell line using MTT assay Inhibitory activity against MCF-7/adr cell line using MTT assay	[PMID: 10780913]
NCI-H226	IC₅₀	1.01 μM Compound: 1	Inhibitory activity against NCI-H226 cell line using MTT assay(mutant p53) Inhibitory activity against NCI-H226 cell line using MTT assay(mutant p53)	[PMID: 10780913]
NCI-H322M	IC₅₀	0.21 μM Compound: 1	Inhibitory activity against NCI-H322 cell line using MTT assay(mutant p53) Inhibitory activity against NCI-H322 cell line using MTT assay(mutant p53)	[PMID: 10780913]
NCI-H358	IC₅₀	0.15 μM Compound: 1	Inhibitory activity against NCI-H358 cell line using MTT assay(mutant p53) Inhibitory activity against NCI-H358 cell line using MTT assay(mutant p53)	[PMID: 10780913]
NCI-H460	IC₅₀	0.06 μM Compound: 1	Inhibitory activity against NCI-H460 cell line using MTT assay Inhibitory activity against NCI-H460 cell line using MTT assay	[PMID: 10780913]
NCI-H460	IC₅₀	0.06 μM Compound: 1	Inhibitory activity against NCI-H460 cell line using MTT assay(Wild type p53) Inhibitory activity against NCI-H460 cell line using MTT assay(Wild type p53)	[PMID: 10780913]
NCI-H460	IC₅₀	0.2 μM Compound: 1	Inhibitory activity against H460pv8 cell line using MTT assay Inhibitory activity against H460pv8 cell line using MTT assay	[PMID: 10780913]
NCI-H647	IC₅₀	0.07 μM Compound: 1	Inhibitory activity against NCI-H647 cell line using MTT assay(mutant p53) Inhibitory activity against NCI-H647 cell line using MTT assay(mutant p53)	[PMID: 10780913]
OVCAR-8	IC₅₀	1.4 μM Compound: Amsacrine	Antiproliferative activity against human OVCAR8 cells after 72 hrs by MTT assay Antiproliferative activity against human OVCAR8 cells after 72 hrs by MTT assay	[PMID: 22546208]
P388	IC₅₀	0.15 μM Compound: mAMSA	In Vitro Cytotoxicity was measured by quantifying clonogenic survival in soft agar following a 1 hr transient exposure of P388 mouse leukemia cells to compound In Vitro Cytotoxicity was measured by quantifying clonogenic survival in soft agar following a 1 hr transient exposure of P388 mouse leukemia cells to compound	10.1016/0960-894X(96)00230-2
P388	IC₅₀	0.15 μM Compound: mAMSA	In vitro cytotoxicity measured by quantifying clonogenic survival in soft agar following a 1-hour transient exposure of p388 mouse leukemia cells. In vitro cytotoxicity measured by quantifying clonogenic survival in soft agar following a 1-hour transient exposure of p388 mouse leukemia cells.	[PMID: 9733489]
P388	IC₅₀	229 nM Compound: m-AMSA	Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay	[PMID: 2778449]
PBMC	IC₅₀	21.7 μM Compound: Amsacrine	Cytotoxicity against human PBMC after 72 hrs by alamar blue assay Cytotoxicity against human PBMC after 72 hrs by alamar blue assay	[PMID: 22546208]
PC-3	IC₅₀	3.3 μM Compound: Amsacrine	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 22546208]
RAW264.7	CC₅₀	95.5 μM Compound: m-Amsa	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31421632]
SF-295	IC₅₀	0.5 μM Compound: Amsacrine	Antiproliferative activity against human SF295 cells after 72 hrs by MTT assay Antiproliferative activity against human SF295 cells after 72 hrs by MTT assay	[PMID: 22546208]
SK-BR-3	IC₅₀	0.06 μM Compound: 1	Inhibitory activity against SKBR-3 cell line using MTT assay (ER-amplified erB2,mutant p53) Inhibitory activity against SKBR-3 cell line using MTT assay (ER-amplified erB2,mutant p53)	[PMID: 10780913]
SW480	IC₅₀	27.7 μM Compound: m-AMSA	Cytotoxicity against human SW480 cells after 72 hrs by MTT assay Cytotoxicity against human SW480 cells after 72 hrs by MTT assay	[PMID: 19364657]
SW480	IC₅₀	27.7 μM Compound: Amsacrine	Antiproliferative activity against human SW480 cells after 72 hrs by MTT assay Antiproliferative activity against human SW480 cells after 72 hrs by MTT assay	[PMID: 18035542]
SW-620	IC₅₀	0.3 μM Compound: Amsacrine	Antiproliferative activity against human SW620 cells after 72 hrs by MTT assay Antiproliferative activity against human SW620 cells after 72 hrs by MTT assay	[PMID: 22546208]
SW-620	IC₅₀	16.7 μM Compound: m-AMSA	Cytotoxicity against human SW620 cells after 72 hrs by MTT assay Cytotoxicity against human SW620 cells after 72 hrs by MTT assay	[PMID: 19364657]
SW-620	IC₅₀	16.7 μM Compound: Amsacrine	Antiproliferative activity against human SW620 cells after 72 hrs by MTT assay Antiproliferative activity against human SW620 cells after 72 hrs by MTT assay	[PMID: 18035542]
T47D	IC₅₀	0.22 μM Compound: 1	Inhibitory activity against T47D cell line using MTT assay (ER+,mutant p53) Inhibitory activity against T47D cell line using MTT assay (ER+,mutant p53)	[PMID: 10780913]
T47D	IC₅₀	0.94 μM Compound: m-Amsa	Cytotoxicity against human T47D cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human T47D cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31421632]
U-937	IC₅₀	0.08 μM Compound: m-AMSA	Antiproliferative against human U937 cells incubated for 72 hrs by MTT assay Antiproliferative against human U937 cells incubated for 72 hrs by MTT assay	[PMID: 31635931]
U-937	IC₅₀	0.61 μM Compound: m-AMSA	Antiproliferative activity against human U937 cells after 48 hrs by MTT assay Antiproliferative activity against human U937 cells after 48 hrs by MTT assay	[PMID: 29954683]
U-937	IC₅₀	0.61 μM Compound: m-AMSA	Antiproliferative activity against human U937 cells after 48 hrs by MTT assay Antiproliferative activity against human U937 cells after 48 hrs by MTT assay	[PMID: 28511910]
V79	IC₅₀	5.8 μM Compound: Amsacrine	Cytotoxicity against chinese hamster V79 cells after 72 hrs by MTT assay Cytotoxicity against chinese hamster V79 cells after 72 hrs by MTT assay	[PMID: 22546208]
ZR-75-1	IC₅₀	0.18 μM Compound: 1	Inhibitory activity against ZR-75-1 cell line using MTT assay (ER+,pgr+,mutant p53) Inhibitory activity against ZR-75-1 cell line using MTT assay (ER+,pgr+,mutant p53)	[PMID: 10780913]

体外研究
(In Vitro)

Amsacrine (m-AMSA) 以浓度依赖性方式阻断 HEK 293 细胞和爪蟾卵母细胞中的 HERG 电流，IC₅₀ 值分别为 209.4 nm 和 2.0 μM。Amsacrine 会导致激活 (-7.6 mV) 和失活 (-7.6 mV) 的电压依赖性发生负偏移。Amsacrine对 HERG 电流的阻断与频率无关^[1]。使用不同浓度的 Amsacrine 对正常人淋巴细胞进行的体外研究表明，染色体畸变水平增加，范围从 8% 到 100%，并且 SCEs 增加，在研究的最低浓度下是正常水平的 1.5 倍 (0.005 μg/mL) 至正常值 (0.25 μg/mL) 的 12 倍^[3]。Amsacrine 诱导的 U937 细胞凋亡的特征在于 caspase-9 和 caspase-3 激活、细胞内 Ca²⁺ 浓度增加、线粒体去极化和 MCL1 下调。Amsacrine 通过降低其稳定性来诱导 MCL1 下调。此外，Amsacrine 处理的 U937 细胞显示出 AKT 降解和 Ca²⁺ 介导的 ERK 失活^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

在用不同剂量的 Amsacrine (0.5-12 mg/kg) 处理的动物中，微核多染红细胞的频率在用 9 和 12 mg/kg 处理后显著增加。此外，本研究首次证明 Amsacrine (m-AMSA) 在体内有丝分裂期具有高致染色体断裂发生率和低致染色体断裂发生率，而诺考达唑在有丝分裂期具有高致染色体断裂发生率和低致染色体断裂发生率^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

393.46

Formula

C₂₁H₁₉N₃O₃S

CAS 号

51264-14-3

性状

固体

颜色

Orange to red

中文名称

安吖啶；胺苯吖啶

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

溶解性数据

细胞实验：

DMSO 中的溶解度 : 9.3 mg/mL (23.64 mM; 超声加热助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.5416 mL	12.7078 mL	25.4155 mL
5 mM	0.5083 mL	2.5416 mL	5.0831 mL
10 mM	0.2542 mL	1.2708 mL	2.5416 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C储存时，请在2年内使用， -20°C储存时，请在1年内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.35 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.95%

选择批次：

Data Sheet (652 KB) SDS (419 KB)

COA (294 KB) LCMS (267 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Thomas D, et al. Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacrine: mode of action. Br J Pharmacol. 2004 Jun;142(3):485-94. [Content Brief]

[2]. Attia SM. Molecular cytogenetic evaluation of the mechanism of genotoxic potential of amsacrine and nocodazole in mouse bone marrow cells. J Appl Toxicol. 2013 Jun;33(6):426-33. [Content Brief]

[3]. Kao-Shan CS, et al. Cytogenetic effects of amsacrine on human lymphocytes in vivo and in vitro. Cancer Treat Rep. 1984 Jul-Aug;68(7-8):989-97. [Content Brief]

[4]. Lee YC, et al. Amsacrine-induced apoptosis of human leukemia U937 cells is mediated by the inhibition of AKT- and ERK-induced stabilization of MCL1. Apoptosis. 2016 Oct 19 [Content Brief]

Animal Administration ^[2]	Amsacrine (m-AMSA) is investigated in three separated experiments. In the first experiment, animals are treated by intraperitoneal injection with 0.5, 1.5 and 4.5 mg/kg of amsacrine and bone marrow is sampled 24 h after treatment. Preliminary negative MN results at this sampling time lead to the use of 30 h sampling time for amsacrine. Thus, in the second experiment, mice are treated with 0.5, 1.5 and 4.5 mg/kg of Amsacrine (m-AMSA) and bone marrow is sampled 30 h after treatment. The doses and sampling times for amsacrine are chosen by reference to earlier studies and the selected doses are within the dose range used for human chemotherapy. The results again show that the micronuclei frequency in the bone marrow of mice is not affected by treatment with any of the selected doses of the test agent, at 30 h sampling time, thus, in the third experiment, mice are treated with 6, 9 and 12 mg/kg of amsacrine and bone marrow is sampled 24 and 30 h after treatment. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Thomas D, et al. Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacrine: mode of action. Br J Pharmacol. 2004 Jun;142(3):485-94. [Content Brief] [2]. Attia SM. Molecular cytogenetic evaluation of the mechanism of genotoxic potential of amsacrine and nocodazole in mouse bone marrow cells. J Appl Toxicol. 2013 Jun;33(6):426-33. [Content Brief] [3]. Kao-Shan CS, et al. Cytogenetic effects of amsacrine on human lymphocytes in vivo and in vitro. Cancer Treat Rep. 1984 Jul-Aug;68(7-8):989-97. [Content Brief] [4]. Lee YC, et al. Amsacrine-induced apoptosis of human leukemia U937 cells is mediated by the inhibition of AKT- and ERK-induced stabilization of MCL1. Apoptosis. 2016 Oct 19 [Content Brief]

Animal Administration
^[2]

Amsacrine (m-AMSA) is investigated in three separated experiments. In the first experiment, animals are treated by intraperitoneal injection with 0.5, 1.5 and 4.5 mg/kg of amsacrine and bone marrow is sampled 24 h after treatment. Preliminary negative MN results at this sampling time lead to the use of 30 h sampling time for amsacrine. Thus, in the second experiment, mice are treated with 0.5, 1.5 and 4.5 mg/kg of Amsacrine (m-AMSA) and bone marrow is sampled 30 h after treatment. The doses and sampling times for amsacrine are chosen by reference to earlier studies and the selected doses are within the dose range used for human chemotherapy. The results again show that the micronuclei frequency in the bone marrow of mice is not affected by treatment with any of the selected doses of the test agent, at 30 h sampling time, thus, in the third experiment, mice are treated with 6, 9 and 12 mg/kg of amsacrine and bone marrow is sampled 24 and 30 h after treatment.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献

[1]. Thomas D, et al. Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacrine: mode of action. Br J Pharmacol. 2004 Jun;142(3):485-94. [Content Brief]

[2]. Attia SM. Molecular cytogenetic evaluation of the mechanism of genotoxic potential of amsacrine and nocodazole in mouse bone marrow cells. J Appl Toxicol. 2013 Jun;33(6):426-33. [Content Brief]

[3]. Kao-Shan CS, et al. Cytogenetic effects of amsacrine on human lymphocytes in vivo and in vitro. Cancer Treat Rep. 1984 Jul-Aug;68(7-8):989-97. [Content Brief]

[4]. Lee YC, et al. Amsacrine-induced apoptosis of human leukemia U937 cells is mediated by the inhibition of AKT- and ERK-induced stabilization of MCL1. Apoptosis. 2016 Oct 19 [Content Brief]

Amsacrine 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.5416 mL	12.7078 mL	25.4155 mL	63.5389 mL
	5 mM	0.5083 mL	2.5416 mL	5.0831 mL	12.7078 mL
	10 mM	0.2542 mL	1.2708 mL	2.5416 mL	6.3539 mL
	15 mM	0.1694 mL	0.8472 mL	1.6944 mL	4.2359 mL
	20 mM	0.1271 mL	0.6354 mL	1.2708 mL	3.1769 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Amsacrine51264-14-3m-AMSA acridinyl anisidide安吖啶胺苯吖啶TopoisomeraseAutophagyInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

Amsacrine (Synonyms: 安吖啶; m-AMSA; acridinyl anisidide)

Customer Review

Other Forms of Amsacrine:

MCE 顾客使用本产品发表的 5 篇科研文献

Amsacrine 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Topoisomerase 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Amsacrine 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Amsacrine (Synonyms: 安吖啶; m-AMSA; acridinyl anisidide)

Customer Review

Other Forms of Amsacrine:

Amsacrine 相关抗体

MCE 顾客使用本产品发表的 5 篇科研文献

Amsacrine 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Topoisomerase 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

Amsacrine 相关抗体:

摩尔计算器

稀释计算器

Amsacrine 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z